Fortress Biotech, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)

12 Months Ended

Dec. 31, 2014

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following table classifies into the fair value hierarchy, financial instruments measured at fair value on a recurring basis in the accompanying Consolidated Balance Sheets as of December 31, 2014; at December 31, 2013, the Company had no investments at fair value:

	Fair Value Measurement as of December 31, 2014
($ in thousands)	Level 1		Level 2	Level 3		Total
Assets
Marketable securities:
U.S. treasury bills	$	19,998	$	$		$	19,998
Mutual funds		4					4
Total marketable securities		20,002					20,002
Long-Term Investments, at fair value (1)					4,160		4,160
Total	$	20,002	$	$	4,160	$	24,162

Schedule of changes in fair value of financial instruments

The table below provides a rollforward of the changes in fair value of Level 3 financial instruments for the year ended December 31, 2014:

	Fair Value of Investments
	Short-term		Long-term
($ in thousands)	Other		Other		CB Pharma		Total
Balance at December 31, 2013	$		$		$		$
Purchases		293		250		2,675		3,218
Change in fair value of investment		(293)				1,235		942
Balance at December 31, 2014	$		$	250	$	3,910	$	4,160